FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Sunday

 

Meat, Sausage and other foods can heighten risks of Multiple Sclerosis

(Posted By: Josi Creek)


Opinion from examination of information from seven EU countries introduced today by German epidemiologist Dr. Klaus Lauer, at the 20th Meeting of the European Neurological Society (ENS) in Berlin, Germany, stated that the facts presented as of currently are not affirmed informal link, but is an expressive implication that a link possibly does exist and needs to be completely researched.

Read more »

Wednesday

 

Multiple Sclerosis treatment, daclizumab in final clinical trial stage

(Posted By: Josi Creek)

Abbott Laboratories and its Massachusetts biotech partner have launched a final-stage clinical trial of their experimental treatment for multiple sclerosis.


The first patient — out of 1,500 needed worldwide — was enrolled last month in the U.S. The drug, daclizumab, is being developed for monthly injection under the patient’s skin by North Chicago-based Abbott and Cambridge-based Biogen Idec.



Read more »

Labels: , , ,


Tuesday

 

NIH Denies Request For Federal Funding to Study New Stem Cell Lines

(Posted By: Josi Creek)


A private lab’s request for federal funds to study 47 new stem cell colonies has been denied by National Institutes of Health  director Francis Collins. The rejection comes after an advisory committee recommended against the approval citing the request violated strict ethical guidelines. Many scientists had hoped for an approval that would give them the ability to study various mutations of diseases. Diseases that were proposed to be studied included Huntington’s disease, cystic fibrosis and multiple sclerosis.  Scientists believe the studying of these stem cell lines could have led to treatments for many of these incurable and often times deadly conditions.



Read more »

Labels: ,


Monday

 

Multiple Sclerosis in a War Zone

(Posted By: Josi Creek)


Can multiple sclerosis attacks be minimized in a war zone?

*An earlier study has shown that the stress of the Second Lebanon War in Israel increased the frequency of attacks in multiple sclerosis (MS) patients. The present study reveals that a potential way to minimize MS exacerbation is by directly coping with the situation. *
Read more »

Labels: ,


Sunday

 

GW Pharmaceuticals Sativex Cannabis is Psychoactive Free

(Posted By: Josi Creek)


Even if you were to track down the location and break into the computer-controlled greenhouse, the cannabis plants you would find at GW Pharmaceuticals' top-secret farm would be unlikely to give you the high you were hoping for.

Read more »

Labels: ,


 

Study: Quality of care in Multiple Sclerosis

(Posted by: Josi Creek)

Labels:


Saturday

 

Study: Sativex effective on spasticity in people with multiple scleros

(Posted By: Josi Creek)

Labels: , ,


 

Study: Alzheimer’s Drug Memantine Not Effective in treating Multiple Sclerosis Cognitive Impairment

(Posted By: Josi Creek)

Labels: ,


 

Two-year study of cervical cord volume and myelin water in primary progressive multiple sclerosis

(Posted By: Josi Creek)

Labels:


 

Study: Strains of Epstein-Barr virus infecting multiple sclerosis patients

(Posted By: Josi Creek)

Labels:


 

High-dose immunoablation with stem cell transplant in aggressive multiple sclerosis: a 10 year study

(Posted By: Josi Creek)

Labels: ,


 

Study: Psychiatric Symptoms at the onset of Multiple Sclerosis

(Posted By: Josi Creek)

Labels:


Friday

 

GW Pharmaceuticals cannabis-based drug Sativex approved

(Posted By: Josi Creek)


A ground-breaking cannabis-based drug for treating symptoms of multiple sclerosis has been approved in Britain, in a landmark decision for its creator GW Pharmaceuticals.


Read more »

Labels: ,


 

Novartis' Gilenya Pill May Shake Up Global MS Market

(Posted By: Josi Creek)


Novartis AG's  novel multiple sclerosis pill Gilenya holds the potential to shake up the $10 billion multiple sclerosis market and give the Swiss pharmaceuticals giant a cutting edge over rivals such as Irish drug maker Elan Corp. PLC , U.S.-based Biogen Idec Inc. and Germany's Merck KGaA.

Read more »

Labels: , , , , ,


Wednesday

 

Biogen Reports 6 More Brain Infection Cases In Tysabri Users

(Posted By: Josi Creek)

Biogen Idec Inc. (BIIB) disclosed six more cases of a rare brain infection in multiple sclerosis patients on Tysabri, which it sells with Elan Corp. (ELN), bringing the total number of cases to 55 as of June 7.



Read more »

Labels: , ,


 

Breakthrough Finding from Israel may Lead to Earlier Diagnosis Multiple Sclerosis

(Posted By: Josi Creek)


A breakthrough finding from Israel may lead to earlier diagnosis, more effective intervention, and perhaps even a cure for the autoimmune disease multiple sclerosis.

"Those who will develop MS will show a different blood signature from those who will not," Prof. Anat Achiron, director of the Multiple Sclerosis Center at Sheba Medical Center.


Read more »

Labels: ,


 

Study Provides Evidence that Add-on Rituximab Reduces Gadolinium-enhancing Brain Lesions in Multiple Sclerosis.

(Posted By: Josi Creek)

This is a study that shows very promising results for Rituximab. 

Labels: ,


 

Zamboni Says Vein Procedure Should be Offered in Clinical Trial

(Posted By: Josi Creek)

People with multiple sclerosis should be able to have surgery on blocked neck veins as part of a clinical trial, says the Italian doctor who pioneered what has become known as the liberation therapy.

Read more »

Labels: ,


Tuesday

 

Biogen Idec Announces Enrollment of First Patient in Oral Therapy Combination Trial in Multiple Sclerosis

(Posted By: Josi Creek)


Biogen Idec today announced enrollment of the first patient in a multicenter Phase II clinical trial designed to evaluate its investigational oral therapy BG-12 (dimethyl fumarate, tecfidera) in combination with commonly used first-line treatments in patients with relapsing-remitting multiple sclerosis (RRMS). The trial, called EXPLORE, will evaluate the safety and tolerability of BG-12 when administered with beta interferons (IFNB) or glatiramer acetate (GA) to patients who continue to have evidence of disease activity despite receiving consistent monotherapy for at least a year ,



Read more »

Labels: ,


 

Genzyme's MS drug, Alemtuzumab gets FDA fast track

(Posted By: Josi Creek)

Genzyme's multiple sclerosis drug candidate, Alemtuzumab was granted fast track status by the Food and Drug Administration, the company said Monday.



The FDA grants fast track status to drug candidates that are designed to treat serious diseases, and which may be superior to current therapies. Fast track status includes additional collaboration between Genzyme and the FDA, and will allow Genzyme to submit portions of its application for the drug alemtuzumab as they are completed, rather than when all clinical testing is complete.
It also means alemtuzumab could get approved more quickly. Drugs that receive fast track status are more likely to get a priority review, which is complete in six months instead of the usual 10 months.

 

Study: Changes in B- and T-cells & Chemokine Levels With Rituximab Treatment in Multiple Sclerosis

(Posted By: Josi Creek)

"In subjects with multiple sclerosis, B cells are critical for T-cell trafficking into the central nervous system and may alter the process by influencing chemokine production within the central nervous system."

Labels: ,


 

Study: Mental Activity protects against disease-related cognitive impairment associated with multiple sclerosis.

(Posted By: Josi Creek)

Labels: ,


 

Study: Stem Cell Transplant Fails to Halt Demyelination: Inflammation of Multiple Sclerosis

(Posted By: Josi Creek)


 "Demyelinating and inflammatory activities of MS persisted after allo-HSCT (allogeneic hematopoietic stem cell transplantation) in all of the patients with MS. Active and chronic active MS lesions exhibited significantly higher numbers of CD3+ T cells and CD8+ cytotoxic T cells and significantly higher scores of CD68+ microglia/macrophages than did chronic inactive lesions or normal-appearing white matter. The normal-appearing brains of allo-HSCT recipients who did not have MS were found to have significantly higher numbers of CD3+ T cells and CD8+ cytotoxic T cells and higher scores of CD68+ microglia/macrophages compared with the controls; however, no demyelination was identified in these non-MS samples."

Labels: ,


Saturday

 

Elan dealt a blow as rival drug, Gilenya, approved

(Posted By: Josi Creek)

ELAN, the Athlone-based pharmaceuticals company, has been dealt a blow after a rival to one of its leading drugs was approved by US regulators. The share dealt 2.5pc lower in New York yesterday.



Read more »

Labels: ,


 

Virus can make immune cells attack nerves in multiple sclerosis

(Posted By: Josi Creek)


In young adults afflicted with multiple sclerosis (MS), a virus infection can incite the body to attack its own nerve tissue by activating unusual, disease-fighting cells with receptors for both viral and nerve proteins.
Read more »

Labels:


Friday

 

Natalizumab an Alternative for Those in Whom Other MS Treatments Have Failed

(Posted By: Josi Creek)

 A new study suggests that patients with relapsing-remitting multiple sclerosis (RRMS) in whom previous treatment regimens have failed remain stable or show improvement when switched to treatment with natalizumab (Tysabri, Novartis).



Read more »

Labels: , , , , , ,


 

Team to test theory of vein efficiency in Multiple Sclerosis patients, and how to detect it

(Posted By: Josi Creek)

B.C. doctors will be part of a $2.4-million, two-year research study to look at whether a controversial treatment for multiple sclerosis is legitimate.



Read more »

Labels:


 

FDA panel recommends approval of first oral drug for multiple sclerosis

(Posted By: Josi Creek)

A Food and Drug Administration advisory panel on Thursday unanimously recommended approval of the first drug for multiple sclerosis (MS) that can be taken orally. Existing drugs for the disease have to be given intravenously or by injection. The new drug, targeted initially at relapsing-remitting MS, is called fingolimod and its manufacturer, Novartis, plans to use the brand name Gilenya. The agency is not required to follow the recommendations of its advisory panels, but it generally does. 



Read more »

Labels:


 

Exercise Helps Multiple Sclerosis Patients

(Posted By: Josi Creek)

Patients with multiple sclerosis (MS) are able to exercise longer when they take intermittent rest breaks, according to a new study presented here at the Consortium of Multiple Sclerosis Centers 24th Annual Conference and the Third Joint Meeting of Americas Committee for Treatment and Research in Multiple Sclerosis.



Read more »

Labels: ,


 

Vitamin D Linked to Poor Learning Performance in Patients With MS

(Posted By: Josi Creek)


 A new study shows that serum vitamin D deficiency is associated with poor learning performance among patients with multiple sclerosis (MS). The research was presented here at the Consortium of Multiple Sclerosis Centers 24th Annual Conference and the Third Joint Meeting of Americas Committee for Treatment and Research in Multiple Sclerosis.
Read more »

Labels: ,


 

Physical Therapy Improves Urinary Symptoms in Patients With Multiple Sclerosis

(Posted By: Josi Creek)

A physical therapy regimen improves both urinary incontinence and urinary retention in patients with multiple sclerosis (MS), according to a study presented here at the Consortium of Multiple Sclerosis Centers 24th Annual Conference and the Third Joint Meeting of Americas Committee for Treatment and Research in Multiple Sclerosis.



Read more »

Labels: ,


 

Vitamin D Exposure in Childhood Linked to Age at Onset of MS

(Posted By: Josi Creek)

Levels of childhood sun exposure and the presence or absence of cod liver oil supplements predict age at onset of multiple sclerosis (MS), a new study suggests.



Read more »

Labels: ,


Thursday

 

New Multiple Sclerosis Drug , Gilenya (Fingolimod), Expected to be Approved by FDA

(Posted By: Josi Creek)

The panel that recommends drug approvals to the FDA has unanimously agreed that the multiple sclerosis drug, fingolimod is safe and effective. The panel is comprised of 25 medical experts not employed by the FDA. The proposed drug is manufactured by the Swiss company Novartis and would be marketed under the name Gilenya. If approved, the drug is expected to bring in more than one billion dollar in annual sales for the company.


Read more »

Labels:


Wednesday

 

Vitamin D Linked to Poor Learning Performance in Patients With Multiple Sclerosis

(Posted By: Josi Creek)

A new study shows that serum vitamin D deficiency is associated with poor learning performance among patients with multiple sclerosis (MS). The research was presented here at the Consortium of Multiple Sclerosis Centers 24th Annual Conference and the Third Joint Meeting of Americas Committee for Treatment and Research in Multiple Sclerosis.



Read more »

Labels:


 

New Adult Stem-Cell Treatments Advance

(Posted By: Josi Creek)

New reports indicate that real hope for ‘miracle’ treatments using adult stem cells is on the way for those suffering from diseases afflicting both the brain and the heart.



Read more »

Labels: ,


Tuesday

 

Novartis’ Multiple Sclerosis Pill, Gilenya, Faces FDA Review

(Posted By: Josi Creek)

Novartis AG’s drug Gilenya has risks that may outweigh its benefit in treating multiple sclerosis, according to U.S. regulators reviewing whether to approve the first pill to slow progression of the disease.
Read more »

Labels: ,


Monday

 

Postpartum Steroids Reduce Multiple Sclerosis Relapses

(Posted By: Josi Creek)

 A single dose of methylprednisolone given to new mothers with multiple sclerosis immediately after delivery reduced the risk of relapse for up to three months, researchers found.


Read more »

Labels:


 

Biogen’s CEO Retires Tomorrow

(Posted By: Josi Creek)

Biogen Idec will officially be CEO-less starting tomorrow. James Mullen, Biogen’s chief executive, retires on June 8 after a decade on the job and the Cambridge, MA-based company hasn’t named his successor.



Read more »

Labels:


 

Simple eye test measures damage from multiple sclerosis

(Posted By: Josi Creek)

A quick, painless eye measurement shows promise as a way to diagnose multiple sclerosis in its very early stages, and to track the effectiveness of treatments, researchers from UT Southwestern Medical Center have found in a multicenter study. "This technique has the potential to provide a powerful and reliable assessment strategy to measure structural changes in the central nervous system, both for diagnostic purposes and in clinical trials to monitor whether potential treatments can prevent deterioration or restore nerve function," said Dr. Elliot Frohman, professor of neurology and ophthalmology, director of the Multiple Sclerosis Clinical Center at UT Southwestern and co-senior author of the study, which appears in the June issue of Annals of Neurology.


Read more »

Labels:


 

Costa Rica clamps down on dodgy stem cell treatments

(Posted By: Josi Creek)

Costa Rica has put an end to stem cell tourism, saying there's no evidence that the treatments work or are even safe.


Using stem cells from bone marrow, umbilical cords and other sources, Costa Rican clinics have been claiming to offer cures for injuries and degenerative diseases.
Read more »

Labels:


 

Multiple sclerosis patients who took oral fingolimod showed better results than those treated with injected interferon beta-1A,

(Posted By: Josi Creek)

 Multiple sclerosis patients who took the oral investigational agent fingolimod were better able to maintain activities of daily living over a year than those treated with injected interferon beta-1A, according to a study presented here.



Read more »

Labels: , ,


Sunday

 

Bayer launches iPhone app to help people manage their multiple sclerosis treatment

(Posted By: Josi Creek)

This application was unveiled as part of Bayer’s patient support program, BETAPLUS, and it provides patients with injection reminders, injection site rotation assistance and injection history for BETASERON. Moreover, through the Internet, myBETAapp also gives patients access to the BETAPLUS web page from where users can access links to educational tools and get peer support. Patients enrolled in the BETAPLUS program can dial directly to speak to BETA Nurses, who are specially trained in MS.

Labels:


Saturday

 

Investigational Oral Disease Modifying Drug Showing Improved Outcomes For Multiple Sclerosis patients

(Posted By: Josi Creek)

Teriflunomide in Adjunct to Interferon Beta Significantly Improved Outcomes of Multiple Sclerosis Patients
Read more »

Labels:


Friday

 

Safety fears hang over pioneering Novartis Multiple Sclerosis pill

(Posted By: Josi Creek)

"In clinical trials Gilenya has been linked to a range of worrying side effects, including skin cancer, heart problems and infections."


Read more »

Labels: ,


 

New Formulation of Copaxone:Teva Announces Positive Study Results


(Posted By: Josi Creek)


Significantly less pain and fewer injection site reactions were reported by patients receiving the new lower volume injection


Read more »

Labels: ,


Wednesday

 

Stem Cell Therapies for Multiple Sclerosis Now Possible

(Posted By: Josi Creek)

A team of investigators from the University of California in Irvine (UCI) Sue & Bill Gross Stem Cell Research Center have recently made important strides in the field of using stem cells as therapies for mitigating the effects of injuries on the central nervous systems. The investigators managed to discover the mechanisms employed by adult neural stem cells, as they navigate through the human brain to the site of injuries, in order to fix the damages. This is the final piece to a puzzle that, once completely solved, could allow researchers to create new, stem cell-based therapies for inflammatory diseases of the brain, such as, for instance, multiple sclerosis (MS).



Read more »

Labels: ,


Tuesday

 

Study: Epstein-Barr virus antibodies in serum and cerebrospinal fluid from Multiple sclerosis, Chronic Inflammatory Demyelinating Polyradiculoneuropathy and Amyotrophic Lateral Sclerosis.

(Posted By: Josi Creek)

Labels:


 

Copaxone (Glatiramer acetate) recovers microscopic tissue damage in patients with multiple sclerosis

(Posted By: Josi Creek)

Traditional magnetic resonance imaging (MRI) techniques have contributed to the management of multiple sclerosis (MS) but are limited in their ability to detect neuronal damage. Advanced MRI metrics provide assessment of microscopic neuronal changes; however, few studies have examined the effects of MS therapies on these measures. 

Labels: ,


 

A Study On Imaging of Spinal Cord Lesions

(Posted By: Josi Creek)

 

Study: Changes in Multiple Sclerosis Brain as shown on MRI

(Posted By: Josi Creek)

Labels:



Go to Newer News Go to Older News